trial · primary record
Nivolumab
Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1500 |
| Primary completion | 2029-08-25 |
| Primary endpoint | Incidence of Adverse Events (AEs) |
| Registry ID | NCT03899155 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:43:28.330Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03899155
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.